Xeris Biopharma Holdings (XERS) Shares Outstanding (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Shares Outstanding (Entity) data on file, last reported at $172.6 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 10.6% year-over-year to $172.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.6 million (up 10.6% YoY) and the FY2025 annual result came in at $166.2 million, up 11.23% from the prior year.
• Shares Outstanding (Entity) climbed to $172.6 million in Q1 2026, from $166.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $172.6 million in Q1 2026 to a low of $135.5 million in Q1 2022.
• A 5-year average of $147.8 million and a median of $148.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) soared 104.46% — and 2023, when it rose 1.3%.
• Tracing XERS's Shares Outstanding (Entity) over 5 years: stood at $136.3 million in 2022, then grew by 1.36% to $138.1 million in 2023, then climbed by 8.18% to $149.4 million in 2024, then grew by 11.23% to $166.2 million in 2025, then advanced by 3.82% to $172.6 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $172.6 million (Q1 2026), $166.2 million (Q4 2025), and $165.5 million (Q3 2025), per Business Quant data.